| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $3.5M | -39.2% |
| SG&A Expense | $3.7M | +1201.7% |
| Operating Income | -$7.2M | +30.5% |
| Net Income | -$7.7M | +22.5% |
| EPS (Basic) | -$114.19 | -1157.6% |
| EPS (Diluted) | -$114.19 | -1157.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.3M | +94.8% |
| Current Assets | $4.9M | +52.1% |
| Total Assets | $6.7M | +36.7% |
| Current Liabilities | $810K | -54.3% |
| Total Liabilities | $928K | -53.0% |
| Stockholders' Equity | $5.7M | +97.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.8M | +5.9% |
| Capital Expenditures | $307K | -56.4% |
| Investing Cash Flow | -$307K | +56.4% |
| Financing Cash Flow | $10.2M | +819.4% |
| Free Cash Flow | -$8.1M | +9.9% |